Item 5.07 Submission of Matters to a Vote of Security Holders.
On May 28, 2024, Enveric Biosciences, Inc. (the "Company") held its 2024 Annual Meeting of Stockholders (the "2024 Annual Meeting"). A total of 2,827,073 shares of the Company's common stock were present in person or represented by proxy at the 2024 Annual Meeting, which represented 38.75% of the outstanding shares of common stock entitled to vote at the 2024 Annual Meeting and constituted a quorum for the transaction of business. Holders of the Company's common stock were entitled to one vote per share of common stock held as of the close of business on April 1, 2024, the record date for the 2024 Annual Meeting. The matters submitted for a vote and the related results are set forth below. At the Annual Meeting, our stockholders voted on each of the following four matters:
| ● | The election of six directors, to serve until the Company's 2025 annual meeting of stockholders or until their successors are duly elected and qualified ("Election of Directors"); | |
| ● | An advisory vote to approve the compensation of the Company's named executive officers, as disclosed in the proxy statement (the "Say-on-Pay Proposal"); | |
| ● | The ratification of the selection and appointment of Marcum LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024 (the "Auditor Ratification Proposal"); and | |
| ● | An advisory vote on whether the compensation of our named executive officers should occur every one year, every two years, or every three years. ("Say-on-Frequency Proposal"). |
The final vote results for each of these four matters is set forth below.
1. The votes cast on the Election of Directors were as follows:
| Nominee | Votes For | Withheld | Broker Non-Votes | |||||||||
| Michael D. Webb | 767,013 | 107,751 | 1,952,309 | |||||||||
| George Kegler | 509,016 | 365,748 | 1,952,309 | |||||||||
| Frank Pasqualone | 523,495 | 351,269 | 1,952,309 | |||||||||
| Marcus Schabacker, M.D., Ph.D. | 796,830 | 77,934 | 1,952,309 | |||||||||
| Joseph Tucker, Ph.D. | 797,936 | 76,828 | 1,952,309 | |||||||||
| Sheila DeWitt, Ph.D | 795,895 | 78,869 | 1,952,309 |
2. The votes cast on the advisory vote for the Say-on-Pay Proposal were as follows:
| Votes For | Votes Against | Abstentions | Broker Non-Votes | |||||||||||
| 711,513 | 116,232 | 47,019 | 1,952,309 |
3. The votes cast on the Auditor Ratification were as follows:
| Votes For | Votes Against | Abstentions | ||||||||
| 2,485,258 | 170,212 | 171,603 |
4. The votes cast on the advisory vote for the Say-on-Frequency Proposal were as follows:
| One Year | Two Years | Three Years | Abstentions | Broker Non-Votes | ||||||||||||||
| 774,619 | 29,743 | 42,608 | 27,794 | 1,952,309 |
For more information about the foregoing proposals, please see the Company's Proxy Statement for the 2024 Annual Meeting. The results reported above are final voting results. No other matters were considered or voted upon at the meeting.
Attachments
Disclaimer
Enveric Biosciences Inc. published this content on 29 May 2024 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 29 May 2024 20:18:22 UTC.
